RBF Capital’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

RBF Capital’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,637	Closed	-$25K	–	559
2022 Q1	$25K	Hold	4,637	–	–	﹤0.01%	517
2021 Q4	$26K	Hold	4,637	–	–	﹤0.01%	515
2021 Q3	$51K	Hold	4,637	–	–	﹤0.01%	478
2021 Q2	$79K	Hold	4,637	–	–	﹤0.01%	478
2021 Q1	$122K	Hold	4,637	–	–	0.01%	426
2020 Q4	$168K	Hold	4,637	–	–	0.01%	368
2020 Q3	$164K	Hold	4,637	–	–	0.02%	330
2020 Q2	$197K	Buy	+4,637	New	+$313K	0.02%	335

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

RBF Capital's EVFM Position: Q2 2022 in Review

RBF Capital sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 4,637 shares — an estimated $25K sold.

RBF Capital first reported a position in EVFM in Q2 2020 and held it in 8 quarters. The position peaked at $197K in Q2 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

RBF Capital reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
RBF Capital sold 4,637 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $25K.
RBF Capital first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
RBF Capital's Evofem Biosciences, Inc. Common Stock position peaked at $197K in Q2 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on RBF Capital's 13F filing for Q2 2022, filed 15 Aug 2022.